Medtronic EVP exercises options, sells 52,524 shares

Medtronic plc executive Harry Skip Kiil reported mixed equity transactions involving stock options and ordinary shares.

Rhea-AI Filing Summary

Medtronic plc executive Harry Skip Kiil reported mixed equity transactions involving stock options and ordinary shares. On February 19, 2026, he exercised multiple stock options (rights to buy), converting them into ordinary shares at exercise prices reflected as $0.0000 per option in the derivative rows.

On the same date, he conducted several open-market sales of ordinary shares coded as "S," totaling 52,524 shares sold according to the transaction summary. Sale prices for these transactions include individual entries around $97.66 to $97.86, with a footnote stating a weighted average sale price and an actual range from $97.60 to $97.775.

Following these exercises and sales, his directly held ordinary share balance shown in the final row is 32,768 shares. A footnote also notes that this total includes 239 shares acquired through dividend reinvestment since his prior report.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 11 txns

Insider KIIL HARRY SKIP

Role EVP & President Cardiovascular

Sold 52,524 shs ($5.13M)

Approx. gross sale proceeds $5.13M

Approx. exercise cost $4.62M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	30,568	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	19,923	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	385	$0.00	$0.00
Exercise	Ordinary Shares	30,568	$93.08	$2.85M
Exercise	Ordinary Shares	19,923	$87.76	$1.75M
Exercise	Ordinary Shares	385	$80.00	$31K
Sale	Ordinary Shares	1,648	$97.86	$161K
Sale	Ordinary Shares	30,568	$97.6634	$2.99M
Sale	Ordinary Shares	19,255	$97.77	$1.88M
Sale	Ordinary Shares	668	$97.825	$65K
Sale	Ordinary Shares	385	$97.82	$38K

Holdings After Transaction: Stock Option (Right to Buy) — 31,687 contracts (Direct); Ordinary Shares — 32,768 shares (Direct)

Footnotes (2)

1. F1. Includes 239 shares acquired through dividend reinvestment since the last report filed by the reporting person.
2. F2. The price reported is a weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $97.60 to $97.775. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medtronic (MDT) executive Harry Skip Kiil report in this Form 4?

Harry Skip Kiil reported option exercises and share sales involving Medtronic stock. He exercised stock options into ordinary shares and then executed several open-market sales on February 19, 2026, with detailed share counts and prices disclosed for each transaction.

How many Medtronic (MDT) shares did Harry Skip Kiil sell in the reported transactions?

The transaction summary shows he sold 52,524 ordinary shares in total. These were coded as open-market or private sales and were executed at prices around the high $97 range, with a weighted average range between $97.60 and $97.775.

What type of transactions did Harry Skip Kiil execute with Medtronic (MDT) stock options?

He executed multiple “M” coded transactions, which are exercises or conversions of derivative securities. These involved stock options (rights to buy) that were converted into ordinary shares on February 19, 2026, before subsequent open-market sales of some of those shares.

What is Harry Skip Kiil’s Medtronic (MDT) share ownership after these Form 4 transactions?

After the reported exercises and sales, the final non-derivative line shows he directly owns 32,768 ordinary shares. A footnote clarifies that this figure includes 239 shares acquired through dividend reinvestment since his last ownership report.

At what prices were Harry Skip Kiil’s Medtronic (MDT) share sales executed?

Individual sale lines list prices such as $97.86, $97.6634, $97.77, and $97.825 per share. A footnote adds that the weighted average sale price ranged from $97.60 to $97.775 across multiple transactions.

What role does Harry Skip Kiil hold at Medtronic (MDT) in this Form 4?

He is identified as an officer of Medtronic with the title EVP & President Cardiovascular. The Form 4 reports his personal equity activity in Medtronic securities, including option exercises and subsequent ordinary share sales on February 19, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 05:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KIIL HARRY SKIP

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MN 55432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President Cardiovascular

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/19/2026		M		30,568	A	$93.08	64,984(1)	D
Ordinary Shares	02/19/2026		M		19,923	A	$87.76	84,907	D
Ordinary Shares	02/19/2026		M		385	A	$80	85,292	D
Ordinary Shares	02/19/2026		S		1,648	D	$97.86	83,644	D
Ordinary Shares	02/19/2026		S		30,568	D	$97.6634(2)	53,076	D
Ordinary Shares	02/19/2026		S		19,255	D	$97.77	33,821	D
Ordinary Shares	02/19/2026		S		668	D	$97.825	33,153	D
Ordinary Shares	02/19/2026		S		385	D	$97.82	32,768	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$93.08	02/19/2026		M			30,568	08/01/2023	08/01/2032	Ordinary Shares	30,568	$0	11,606	D
Stock Option (Right to Buy)	$87.76	02/19/2026		M			19,923	07/31/2024	07/31/2033	Ordinary Shares	19,923	$0	18,926	D
Stock Option (Right to Buy)	$80	02/19/2026		M			385	07/29/2025	07/29/2034	Ordinary Shares	385	$0	1,155	D

Explanation of Responses:

1. Includes 239 shares acquired through dividend reinvestment since the last report filed by the reporting person.

2. The price reported is a weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $97.60 to $97.775. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder upon request.

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.